ZUMA-5: Phase II Study of Axicabtagene Ciloleucel in R/R Indolent Non-Hodgkin Lymphoma

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Axi-cel, a CD19-directed CAR T-cell therapy, produced high and durable response rates in patients with FL or MZL and ≥ 2 previous lines of therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 246 KB
Released: December 18, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Ashley Leak Bryant, PhD, RN, OCN, FAAN, shares strategies for managing lower-risk myelodysplastic syndromes in this commentary from Clinical Care Options (CCO)

Ashley Leak Bryant, PhD, RN, OCN, FAAN Released: January 14, 2022

On-demand webcast on current and emerging treatment options for MDS featuring 3 faculty experts presented by Clinical Care Options (CCO)

Michael J. Savona, MD
Program Director
Jacqueline S. Garcia, MD Amer Zeidan, MBBS
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 13, 2022 Expired: January 12, 2023

Ashley Leak Bryant, PhD, RN, OCN, FAAN, shares her insights on managing patients with acute myeloid leukemia who are unfit for intensive chemotherapy in this commentary from Clinical Care Options (CCO)

Ashley Leak Bryant, PhD, RN, OCN, FAAN Released: January 13, 2022

In this video from Clinical Care Options (CCO), Drs Michael Bishop, Jesús Berdeja, and Jae Park discuss key data on CAR T-cell therapy

Michael R. Bishop, MD
Program Director
person default Jesús G. Berdeja, MD Jae H. Park, MD
Physicians: maximum of 2.25 AMA PRA Category 1 Credits Released: January 13, 2022 Expired: January 12, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings